Which genetic abnormality is most commonly associated with medulloblastoma and is used for risk stratification?

Explanation

## Medulloblastoma — Genetic Alterations and Risk Stratification **Key Point:** **MYC amplification** (both c-MYC and N-MYC) is the most common and clinically significant genetic abnormality in medulloblastoma, serving as a major prognostic marker and driver of tumor biology. ### Genetic Landscape of Medulloblastoma | Genetic Alteration | Frequency | Prognostic Significance | Clinical Impact | |-------------------|-----------|------------------------|------------------| | **MYC/N-MYC amplification** | 30–40% | **High-risk** | Aggressive, poor prognosis | | **TP53 mutation** | 10–15% | High-risk | Li-Fraumeni association | | **PTEN loss** | 10–15% | Intermediate | Cowden syndrome link | | **WNT pathway activation** | 10–15% | **Favorable** | Better prognosis | | **SHH pathway activation** | 25–30% | Variable | Age-dependent outcome | ### Why MYC Amplification Matters **High-Yield:** N-MYC amplification is the **single most important adverse prognostic factor** in medulloblastoma: 1. **Drives proliferation**: MYC is a transcription factor that promotes cell cycle progression and inhibits differentiation 2. **Associated with metastatic disease**: Amplified tumors are more likely to have M+ (metastatic) stage at diagnosis 3. **Predicts treatment response**: N-MYC amplified tumors show worse response to standard chemotherapy and radiation 4. **Guides therapy intensification**: Patients with N-MYC amplification receive more aggressive treatment protocols ### Molecular Subgroups (WHO 2021) Medianblastomas are now classified into **4 molecular subgroups** based on driver pathways: - **WNT-activated** (favorable prognosis) - **SHH-activated** (intermediate; age-dependent) - **Group 3** (MYC-driven, poor prognosis) - **Group 4** (most common, variable prognosis) **Clinical Pearl:** In clinical practice, **N-MYC status** (amplified vs. non-amplified) is determined by **fluorescence in situ hybridization (FISH)** or **array CGH** and is incorporated into modern risk stratification algorithms. Amplification is defined as ≥4 copies. **Mnemonic:** **MYC = Metastatic, Aggressive, Chemotherapy-resistant** — remember that MYC amplification predicts the worst outcomes. [cite:WHO Classification of Tumours of the Central Nervous System, 5th Edition; Harrison 21e Ch 375]